20 / 21
PARP inhibitors as Therapy( cont´d)
How, When, Who and Why
4.
Why
choose a PARP inhibitor( Rucaparib) as treatment in the EU?
§
Proven Efficacy ( ORR:54% in heavily pretreated patients: 64%
≥3 prior chemotherapies
)
§
Acceptable Toxicity profile: <10% discontinuation due to TEAE.
§
Delay/Replace a new line of Chemotherapy in the patients’ disease journey
:
•
Patients’ desire: no chemotherapy at an specific time point
•
No suitable for further platinum therapy:
ü
Carboplatin Hypersensitivity Reactions(HSR):
•
The risk of developing HSR:
<
1% on first line
up to 27%
in patients with more than
seven cycles of therapy.
•
Long-term toxicites
Oza AM et al.
Gynecol Oncol
. 2017;147:267–275
D H Moon et al. British Journal of Cancer (2013) 109, 1072–1078